Prostate cancer risk among users of finasteride and alpha-blockers - A population based case-control study

European Journal of Cancer

Volumn 43, Issue 4, 2007, Pages 775-781

  Murtola, Teemu J ^a   Tammela, Teuvo L J ^b   Määttänen, Liisa ^c   Hakama, Matti ^a   Auvinen, Anssi ^a,d  

^a UNIVERSITY OF TAMPERE   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c FINNISH CANCER REGISTRY   (Finland)

^d Pathology Laboratory of the Finnish Cancer Society   (Finland)

Author keywords

Case control study; Drug therapy; Epidemiology; Prostatic hyperplasia; Prostatic neoplasms

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; FINASTERIDE; TAMSULOSIN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY;

ADRENERGIC ALPHA-ANTAGONISTS; CASE-CONTROL STUDIES; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; ODDS RATIO; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 33947657075     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.12.001     Document Type: Article

References (25)

1. Ferlay J., Bray F., Pisani P., and Parkin D.M. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5. version 2.0 (2004), IARC Press, Lyon
2. Fong Y.K., Milani S., and Djavan B. Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia. Curr Opin Urol 15 (2005) 35-38
3. Bostwick D.G., Burke H.B., Djakiew D., et al. Human prostate cancer risk factors. Cancer 101 (2004) 2371-2490
4. Ishizuka O., Nishizawa O., Hirao Y., and Ohshima S. Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy. Int J Urol 9 (2002) 607-612
5. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
6. Tahmatzopoulos A., Rowland R.G., and Kyprianou N. The role of alpha-blockers in the management of prostate cancer. Expert Opin Pharmacother 5 (2004) 1279-1285
7. Teppo L., Pukkala E., and Lehtonen M. Data quality and quality control of a population-based cancer registry. Acta Oncol 33 (1994) 365-369
8. Statistics Finland. Finland in figures: population structure. http://www.stat.fi/tup/suoluk/suoluk_vaesto_en.html [accessed 28.11.2006].
9. Martikainen J, Rajaniemi S. Drug reimbursement systems in EU Member States, Iceland and Norway. Helsinki; The Social Insurance Institution, Finland, Social security and health reports 54, 2002. http://www.kela.fi/in/internet/english.nsf/NET/260902150016PB?OpenDocument [accessed 28.11.2006].
10. National Agency for Medicines: Drug consumption in Finland in 2002-2005. http://raportit.nam.fi/raportit/kulutus/laakekulutus_e.htm [accessed 28.11.2006].
11. Koskimaki J., Hakama M., Huhtala H., and Tammela T.L. Prevalence of lower urinary tract symptoms in Finnish men: a population-based study. Br J Urol 81 (1998) 364-369
12. Crawford E.D. Epidemiology of prostate cancer. Urology 62 (2003) 3-12
13. Matikaine M.P., Pukkala E., Schleutker J., et al. Relatives of prostate cancer patients have an increased risk of prostate and stomach cancers: a population-based, cancer registry study in Finland. Cancer Causes Control 12 (2001) 223-230
14. Negri E., Pelucchi C., Talamini R., et al. Family history of cancer and the risk of prostate cancer and benign prostatic hyperplasia. Int J Cancer 114 (2005) 648-652
15. Breslow N., Chan C.W., and Dhom G. Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer 20 (1977) 680-688
16. Franks L.M. Latent carcinoma of the prostate. J Pathol Bact 68 (1954) 603-616
17. Kabalin J.N., McNeal J.E., Price H.M., Freiha F.S., and Stamey T.A. Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphologic observations. J Urol 141 (1989) 1091-1094
18. Montie J.E., Wood D.P., Pontes J.E., Boyett J.M., and Levin H.S. Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer 63 (1989) 381-385
19. Schröder FH, Gosselaar C, Roemeling S, Postma R, Roobol MJ, Bangma CH. PSA and the detection of prostate cancer after 2005. Part I. EAU-EBU Update Series 2006;4: 2-12.
20. Draisma G., Boer R., Otto S.J., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst 95 (2003) 868-878
21. Makinen T., Tammela Tl., Stenman U.H., et al. Second round results of the Finnish population-based prostate cancer screening trial. Clin Cancer Res 10 (2004) 2231-2236
22. Ciatto S., Zappa M., Villers A., Paez A., Otto S.J., and Auvinen A. Contamination by opportunistic screening in the European randomized study of prostate cancer screening. BJU Int 92 (2003) 97-100
23. Fitzpatrick J.M. The natural history of benign prostatic hyperplasia. BJU Int 97 (2006) 3-6
24. Espana F., Martinez M., Royo M., et al. Changes in molecular forms of prostate-specific antigen during treatment with finasteride. BJU Int 90 (2002) 672-677
25. Thompson I.M., Chi C., Ankerst D.P., et al. Effect of finasteride on sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98 (2006) 1128-1133